JP2022504400A - 製造及び治療のためのｄｎａｓｅ酵素の操作 - Google Patents

製造及び治療のためのｄｎａｓｅ酵素の操作 Download PDF

Info

Publication number
JP2022504400A
JP2022504400A JP2021518905A JP2021518905A JP2022504400A JP 2022504400 A JP2022504400 A JP 2022504400A JP 2021518905 A JP2021518905 A JP 2021518905A JP 2021518905 A JP2021518905 A JP 2021518905A JP 2022504400 A JP2022504400 A JP 2022504400A
Authority
JP
Japan
Prior art keywords
seq
variant
amino acid
linker
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021518905A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504400A5 (https=
Inventor
トビアス エー． フックス
アール． アブドゥル ハッキム
Original Assignee
ニュートロリス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニュートロリス インコーポレイテッド filed Critical ニュートロリス インコーポレイテッド
Publication of JP2022504400A publication Critical patent/JP2022504400A/ja
Publication of JP2022504400A5 publication Critical patent/JP2022504400A5/ja
Priority to JP2024133817A priority Critical patent/JP7818850B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2021518905A 2018-10-08 2019-10-08 製造及び治療のためのｄｎａｓｅ酵素の操作 Pending JP2022504400A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024133817A JP7818850B2 (ja) 2018-10-08 2024-08-09 製造及び治療のためのｄｎａｓｅ酵素の操作

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862742682P 2018-10-08 2018-10-08
US62/742,682 2018-10-08
US201862775563P 2018-12-05 2018-12-05
US62/775,563 2018-12-05
US201862779104P 2018-12-13 2018-12-13
US62/779,104 2018-12-13
US201962808601P 2019-02-21 2019-02-21
US62/808,601 2019-02-21
US201962846904P 2019-05-13 2019-05-13
US62/846,904 2019-05-13
PCT/US2019/055178 WO2020076817A1 (en) 2018-10-08 2019-10-08 Engineering of dnase enzymes for manufacturing and therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024133817A Division JP7818850B2 (ja) 2018-10-08 2024-08-09 製造及び治療のためのｄｎａｓｅ酵素の操作

Publications (2)

Publication Number Publication Date
JP2022504400A true JP2022504400A (ja) 2022-01-13
JP2022504400A5 JP2022504400A5 (https=) 2022-10-14

Family

ID=70164727

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021518905A Pending JP2022504400A (ja) 2018-10-08 2019-10-08 製造及び治療のためのｄｎａｓｅ酵素の操作
JP2024133817A Active JP7818850B2 (ja) 2018-10-08 2024-08-09 製造及び治療のためのｄｎａｓｅ酵素の操作

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024133817A Active JP7818850B2 (ja) 2018-10-08 2024-08-09 製造及び治療のためのｄｎａｓｅ酵素の操作

Country Status (12)

Country Link
US (2) US11578314B2 (https=)
EP (1) EP3864147A4 (https=)
JP (2) JP2022504400A (https=)
KR (1) KR20210072790A (https=)
CN (1) CN112996911A (https=)
AU (2) AU2019358915B2 (https=)
BR (1) BR112021006737A2 (https=)
CA (1) CA3115766A1 (https=)
IL (2) IL325846A (https=)
MX (1) MX2021004022A (https=)
SG (1) SG11202103426XA (https=)
WO (1) WO2020076817A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019209770B2 (en) 2018-01-16 2025-07-31 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
EP4161645A4 (en) * 2020-06-08 2023-11-01 Yale University COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING COAGULOPATHY AND/OR SEPSIS IN PATIENTS WITH BACTERIAL AND/OR VIRAL INFECTIONS
EP4294824A4 (en) * 2021-02-17 2025-01-01 Neutrolis Inc. DNASE 1-LIKE 2 MANIPULATED FOR PRODUCTION AND USE IN THERAPY
CA3219838A1 (en) * 2021-05-21 2022-11-24 Dmitry Dmitrievich Genkin Immunomodulation of tumor microenvironment
EP4448743A4 (en) * 2021-12-15 2026-01-14 Univ Texas Tech System IMPROVEMENT IN THE SERUM HALF-LIFE OF DNASE1L3
WO2025076525A1 (en) * 2023-10-06 2025-04-10 Neutrolis, Inc. Biomarker and precision therapy for inflammatory disease
WO2026037276A1 (zh) * 2024-08-12 2026-02-19 上海交通大学医学院 一种减少线粒体dna泄露的方法
CN120424194A (zh) * 2025-04-30 2025-08-05 苏州泓迅生物科技股份有限公司 一种重组人源纤连蛋白的制备方法及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US6482626B2 (en) 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6656685B2 (en) * 2001-01-29 2003-12-02 Ventana Medical Systems, Inc. Hybridization buffers using low molecular weight dextran sulfate and methods for their use
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US20040138156A1 (en) * 2002-02-26 2004-07-15 Schneider Michael C Therapeutic regulation of deoxyribonuclease-1-like-3 activity
EP1440981A3 (en) * 2003-01-21 2005-11-23 Research Association for Biotechnology Full-length human cdna
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US9248166B2 (en) 2003-07-14 2016-02-02 Cls Therapeutics Limited Method for treating oncological diseases
WO2006130034A1 (fr) 2005-04-25 2006-12-07 Dmitry Dmitrievich Genkin Procede pour prolonger la duree de vie d'animaux ou de l'humain
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
RU2269356C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP2416156B1 (en) 2006-10-18 2015-12-30 Periness Ltd. Method for determining a male fertility status
US20090305345A1 (en) 2006-10-23 2009-12-10 Medical Research Council Polymerase
AU2008279550B2 (en) 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
MX341084B (es) * 2009-11-02 2016-08-05 Univ Washington Composiciones de nucleasas terapéuticas y métodos.
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
EP2561367A1 (en) 2010-04-22 2013-02-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations
CN107188970A (zh) 2010-06-04 2017-09-22 株式会社蒂奥姆生物 具有因子vii活性的融合蛋白质
WO2012106264A2 (en) 2011-01-31 2012-08-09 The Trustees Of Columbia University In The City Of New York Treatment and prevention of bacterial vaginosis and gardnerella vaginalis infections
AU2012222833B2 (en) * 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
ES2666303T3 (es) * 2011-04-29 2018-05-03 University Of Washington Composiciones terapéuticas de nucleasa y métodos
WO2012166611A2 (en) 2011-05-27 2012-12-06 Immune Disease Institute, Inc. Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
ES2666856T3 (es) * 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
US9867871B2 (en) 2011-12-12 2018-01-16 The Board Of Trustees Of The University Of Illinois Composition and method for treating nucleic acid-related eye disease
GB201208879D0 (en) 2012-05-21 2012-07-04 London School Hygiene & Tropical Medicine Therapeutic for treating Clostridium difficile infection
WO2014028429A2 (en) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes and polymerases for the synthesis of rna
HRP20192080T1 (hr) 2013-10-31 2020-02-07 Resolve Therapeutics, Llc Terapeutske fuzije nukleaza-albumine i postupci
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
CN107249621A (zh) 2014-09-08 2017-10-13 哥谭生物制药股份有限公司 用于治疗肺结节病的粘液溶解剂
EP3265814B1 (en) 2015-03-01 2020-11-18 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
EP3273238A1 (en) 2016-07-22 2018-01-24 Universitätsklinikum Hamburg-Eppendorf Immunodiagnostic detection of anti-neutrophil antibodies
CA3036926C (en) 2016-09-30 2022-05-31 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
EP3570667B1 (en) * 2017-01-20 2022-11-16 Neutrolis Inc. Animal model for drug development
DK3668972T3 (da) * 2017-08-18 2025-01-13 Neutrolis Inc Konstruerede dnase-enzymer og anvendelse i terapi
US10988746B2 (en) * 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
WO2020163264A1 (en) * 2019-02-04 2020-08-13 Neutrolis, Inc. Engineered human extracellular dnase enzymes for drug candidate selection
EA202190940A1 (ru) * 2019-05-13 2021-10-15 Ньютролис Инк. РАЗРАБОТКА ДНКаз ДЛЯ ПРОИЗВОДСТВА И ТЕРАПИИ
EP4294824A4 (en) * 2021-02-17 2025-01-01 Neutrolis Inc. DNASE 1-LIKE 2 MANIPULATED FOR PRODUCTION AND USE IN THERAPY

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. J., vol. 389, JPN6022039343, 2005, pages 355 - 364, ISSN: 0005128874 *
FEBS, vol. 276, JPN6022039345, 2009, pages 1059 - 1073, ISSN: 0005128875 *
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol. 13, JPN6022039342, 2015, pages 732 - 742, ISSN: 0005128873 *
MOLECULAR THERAPY, vol. 6, no. 1, JPN6022039341, 2002, pages 35 - 42, ISSN: 0005478967 *

Also Published As

Publication number Publication date
SG11202103426XA (en) 2021-05-28
US11578314B2 (en) 2023-02-14
EP3864147A4 (en) 2022-07-06
US12565642B2 (en) 2026-03-03
WO2020076817A1 (en) 2020-04-16
US20240191218A1 (en) 2024-06-13
IL325846A (en) 2026-03-01
IL282058B1 (en) 2026-02-01
EP3864147A1 (en) 2021-08-18
AU2019358915B2 (en) 2025-09-18
CA3115766A1 (en) 2020-04-16
JP7818850B2 (ja) 2026-02-24
MX2021004022A (es) 2021-09-10
AU2025283522A1 (en) 2026-01-15
US20220162575A1 (en) 2022-05-26
JP2024160327A (ja) 2024-11-13
AU2025283522B2 (en) 2026-03-19
AU2019358915A1 (en) 2021-05-20
IL282058A (en) 2021-05-31
BR112021006737A2 (pt) 2021-07-13
CN112996911A (zh) 2021-06-18
KR20210072790A (ko) 2021-06-17

Similar Documents

Publication Publication Date Title
JP7818850B2 (ja) 製造及び治療のためのｄｎａｓｅ酵素の操作
US11840712B2 (en) Engineering of DNASE enzymes for manufacturing and therapy
CZ20031718A3 (cs) Polypeptidická proteáza štěpící von Willebrandův faktor (vWF), nukleová kyselina kódující tento polypeptid a použití tohoto polypeptidu
US20240374643A1 (en) Dnase1-like 3 and its use in therapy
KR102682612B1 (ko) N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도
JP2738428B2 (ja) トロンビンによるプロテインｃの活性化を促進する作用を有するペプチド
NZ237244A (en) Cloning and production of human von willebrand factor analogues and compositions thereof
US20240401015A1 (en) Dnase enzymes engineered for improved stability
RU2183214C2 (ru) Природный и рекомбинантный ингибиторы тромбина, их получение и применение
JP2025538873A (ja) 発現の改善と治療への使用のために操作されたｄｎａｓｅ１－ｌｉｋｅ３
EA052450B1 (ru) РАЗРАБОТКА ДНКаз ДЛЯ ПРОИЗВОДСТВА И ТЕРАПИИ
EA046216B1 (ru) РАЗРАБОТКА ДНКаз ДЛЯ ПРОИЗВОДСТВА И ТЕРАПИИ
WO1991004276A1 (en) Isolated, physiologically active human thrombomodulin polypeptide
RU2845088C2 (ru) Расщепленный с n-конца и/или c-конца растворимый полипептид ph20 и его применение
WO2008059917A1 (en) Thrombin mutant
JPH02268689A (ja) プロテアーゼ発現ベクターおよびそれを用いたプロテアーゼの生産方法
JPWO1991004276A1 (ja) 単離された生理的に活性なヒトトロンボモジュリンポリペプチド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240822

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240925

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20241213